Goldman Sachs Group Inc Keros Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

$596 Billion
Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 740,606 shares of KROS stock, worth $11.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

740,606

Previous 740,606 -0.0%

Holding current value

$11.2 Million

Previous $7.55 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	BUY	$10.15 - $16.1 $2.08 Million - $3.3 Million	205,022 Added 38.28%	740,606 $7.55 Million
Q4 2024 Feb 11, 2025	BUY	$15.64 - $70.0 $2.81 Million - $12.6 Million	179,920 Added 50.59%	535,584 $8.48 Million
Q3 2024 Nov 14, 2024	SELL	$41.68 - $58.07 $6.91 Million - $9.63 Million	-165,783 Reduced 31.79%	355,664 $20.7 Million
Q2 2024 Aug 13, 2024	BUY	$44.58 - $66.89 $11.7 Million - $17.6 Million	263,079 Added 101.82%	521,447 $23.8 Million
Q1 2024 May 15, 2024	BUY	$41.26 - $70.48 $2.2 Million - $3.75 Million	53,269 Added 25.97%	258,368 $17.1 Million
Q4 2023 Feb 13, 2024	BUY	$27.12 - $41.05 $2.85 Million - $4.31 Million	105,040 Added 104.98%	205,099 $8.15 Million
Q3 2023 May 14, 2024	SELL	$31.57 - $43.02 $3.32 Million - $4.52 Million	-105,040 Reduced 51.21%	100,059 $3.19 Million
Q3 2023 Nov 14, 2023	BUY	$31.57 - $43.02 $825,618 - $1.13 Million	26,152 Added 35.39%	100,059 $3.19 Million
Q2 2023 May 14, 2024	BUY	$37.26 - $51.01 $433,967 - $594,113	11,647 Added 18.71%	73,907 $2.97 Million
Q2 2023 Aug 14, 2023	BUY	$37.26 - $51.01 $433,967 - $594,113	11,647 Added 18.71%	73,907 $2.97 Million
Q1 2023 May 14, 2024	SELL	$41.44 - $59.32 $3.46 Million - $4.96 Million	-83,562 Reduced 57.3%	62,260 $2.66 Million
Q1 2023 May 11, 2023	SELL	$41.44 - $59.32 $3.46 Million - $4.96 Million	-83,562 Reduced 57.3%	62,260 $2.66 Million
Q4 2022 May 14, 2024	SELL	$39.45 - $51.77 $1.2 Million - $1.58 Million	-30,542 Reduced 17.32%	145,822 $7 Million
Q4 2022 Feb 13, 2023	SELL	$39.45 - $51.77 $1.2 Million - $1.58 Million	-30,542 Reduced 17.32%	145,822 $7 Million
Q3 2022 May 14, 2024	BUY	$27.8 - $40.12 $792,661 - $1.14 Million	28,513 Added 19.28%	176,364 $6.64 Million
Q3 2022 Nov 10, 2022	BUY	$27.8 - $40.12 $792,661 - $1.14 Million	28,513 Added 19.28%	176,364 $6.63 Million
Q2 2022 May 14, 2024	SELL	$26.03 - $67.04 $1.49 Million - $3.84 Million	-57,248 Reduced 27.91%	147,851 $4.09 Million
Q2 2022 Aug 15, 2022	BUY	$26.03 - $67.04 $521,120 - $1.34 Million	20,020 Added 15.66%	147,851 $4.09 Million
Q1 2022 May 16, 2022	BUY	$42.12 - $59.36 $359,409 - $506,518	8,533 Added 7.15%	127,831 $6.95 Million
Q4 2021 Feb 14, 2022	BUY	$36.95 - $62.89 $2.49 Million - $4.24 Million	67,389 Added 129.82%	119,298 $6.98 Million
Q3 2021 Nov 10, 2021	BUY	$29.27 - $43.71 $1.52 Million - $2.27 Million	51,909 New	51,909 $2.05 Million

Others Institutions Holding KROS

# of Institutions

178

Shares Held

36.4M

Call Options Held

938K

Put Options Held

1.39M

View Full List

About Keros Therapeutics, Inc.

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $389M
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

More about KROS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Keros Therapeutics, Inc. Transaction History